Higgons John Duncan 4
4 · Jounce Therapeutics, Inc. · Filed Jun 29, 2020
Insider Transaction Report
Form 4
Higgons John Duncan
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-06-26+13,550→ 13,550 totalExercise: $7.58Exp: 2030-06-26→ Common Stock (13,550 underlying)
Footnotes (1)
- [F1]The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2021 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors.